Retinal Remodeling

$627,106R01FY2012EYNIH

University Of Utah, Salt Lake City UT

Investigators

Linked publications, trials & patents

Paper 38365085 Paper 37677999 Paper 37440048 Paper 37186528 Paper 36680773 Paper 36635325 Paper 35588744 Paper 35545677 Paper 34487725 Paper 34241625 Paper 33878326 Paper 33794197 Paper 32810483 Paper 32332119 Paper 32207814 Paper 32187524 Paper 32084404 Paper 31988185 Paper 31884639 Paper 31866339 Paper 31417169 Paper 31406197 Paper 31356876 Paper 31078539 Paper 30988181 Paper 30487737 Paper 29877835 Paper 29479126 Paper 29180671 Paper 28973333 Paper 28948967 Paper 28632847 Paper 28396597 Paper 28128337 Paper 27447117 Paper 27223656 Paper 27199657 Paper 27142256 Paper 27064393 Paper 27020758 Paper 26985029 Paper 26808487 Paper 26541886 Paper 26207299 Paper 25825494 Paper 25667740 Paper 25571389 Paper 25237297 Paper 25089879 Paper 24016532 Paper 23595739 Paper 23281397 Paper 23042441 Paper 22644448 Paper 22594836 Paper 22498714 Paper 22325330 Paper 22323724 Paper 22247487 Paper 21985191 Paper 21940995 Paper 21681749 Paper 21311605 Paper 21118201 Paper 20713087 Paper 20598935 Paper 19855814 Paper 19324864 Paper 19172170 Paper 19169423 Paper 18955050 Paper 18483561 Paper 17591910 Paper 16255687 Paper 16139860 Paper 15916760

Abstract

DESCRIPTION (provided by applicant): Aim 1. Establish interventions for early disease in the transgenic rhodopsin P347L (TgP347L) rabbit, a model of human retinitis pigmentosa (RP). TgP347L rabbits (1-30 month old) will receive subretinal injections of shRNA-adeno-associated virus (AAV) to suppress mutant opsin production. Analyses include eye imaging, electroretinograms, visual evoked po- tentials, behavior, immunocytochemistry, Western blots, automated transmission electron micro- scope (ATEM) imaging, and electrophysiology by whole cell and multielectrode arrays. Significance. This is a test of early intervention for human RP in large-eye animal model. Aim 2. Establish optogenetic interventions for late disease in RP. TgP347L rabbits >12mos of age will receive (1) subretinal injections of Channelrhodopsin2 (ChR2)-AAV targeting bipolar cells (BCs) or AII amacrine cell (ACs). Analyses will follow those established in Aim 1. Significance. This is a test of late intervention for human RP in a large-eye animal model. Aim 3. Build pathoconnectomes for early and late stage TgP347L rabbit BCs and AII cells. BCs are known to undergo severe rewiring and reprogramming in RP, but the nature of retargeting is completely unknown. The extent of AII cell remodeling is similarly unknown. Methods. ATEM imaging will be used to characterize remodeling networks. Significance. This is the first attempt to quantitatively define rewiring in any neural system in retina or brain and has profound implications for all neurodegenerative disorders. Aim 4. Evaluate retinoic acid and retinoid receptor-based interventions to attenuate corruptive remodeling and reprogramming. TgP347L rabbits will be treated with retinoid X receptor and- tagonists to block pathologic neuritogenesis. Analysis includes ATEM imaging and molecular profiling as in Aim 1. Significance. This is a test of a potential clinical intervention for remodeling RP in a large-eye animal model. PUBLIC HEALTH RELEVANCE: New RNA inhibition and optogenetics interventions offer potential cures for retinitis pigmentosa (RP), even in the presence neuronal remodeling that impedes other therapies. Discovery of the mechanisms remodeling are facilitating anti-remodeling drug testing that may enhance the effectiveness of gene therapies.

View original record on NIH RePORTER →